Jazz Pharmaceuticals plc (JAZZ)
What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings
Evaluate the expected performance of Jazz (JAZZ) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth
Jazz (JAZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock?
Investors need to pay close attention to Jazz Pharmaceuticals stock based on the movements in the options market lately.
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
Jazz Pharmaceuticals plc (JAZZ) Discusses HERIZON-GEA-01 Phase III Trial Results for Zanidatamab in HER2+ GEA Transcript
Jazz Pharmaceuticals: A Strong Buy Due To Execution In Oncology
Jazz Pharmaceuticals plc is deeply undervalued, trading at 2.4x sales, as the market overlooks its oncology pivot and robust growth catalysts. Ziihera's Phase 3 data surpassing Herceptin signals a transformative 'pipeline in a product' opportunity, targeting multi-billion-dollar HER2+ cancer market. Zepzelca's expanded front-line SCLC approval and Epidiolex's blockbuster trajectory underpin near-term revenue growth and portfolio diversification.
Jazz (JAZZ) Up 24.5% Since Last Earnings Report: Can It Continue?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?
Trials, Sales Wins Sends Jazz Pharmaceuticals Higher
Jazz Pharmaceuticals PLC (JAZZ) shares up 352% since Big Money bought big in 2015.
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Jazz Pharmaceuticals plc (JAZZ) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data
Jazz jumps to a 52-week high after HERIZON-GEA-01 shows Ziihera combos delivering meaningful PFS and OS gains in HER2+ GEA.
Jazz Pharmaceuticals: Stock Soars On Zanidatamab Data - I'm Still On The Fence
Jazz Pharmaceuticals plc surged over 20% after positive Phase 3 data for Ziihera in HER2+ gastroesophageal cancer. JAZZ's diversified portfolio, strong Q3 earnings, and upgraded 2025 revenue guidance support its current double-digit billion valuation. Key risks include upcoming patent expiries, new competition for Xywav, and uncertainty around long-term profitability and revenue replacement.
Why Jazz (JAZZ) International Revenue Trends Deserve Your Attention
Review Jazz's (JAZZ) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
